USFDA Refuses Permission to Drugs Manufactured at 3 IPCA Units
DSIJ Intelligence / 16 Jun 2017
Ipca Laboratories Limited is engaged in pharmaceuticals business. The company is a manufacturer and supplier of active pharmaceutical ingredients (APIs).
The U.S. FDA has refused admission to all drugs manufactured at IPCA's Pithampur and Silvassa facility. The ban will continue until the company can demonstrate that the drugs manufactured from these manufacturing sites and intended for the US market are in compliance with the current good manufacturing practice regulation (CGMP), stated a BSE filing.
Ipca Laboratories Limited is engaged in pharmaceuticals business. The company is a manufacturer and supplier of active pharmaceutical ingredients (APIs).
The BSE filing further revealed that all drugs except API Chloroquine Phosphate made at Ratlam (Madhya Pradesh) unit have also been denied entry in the US.
Meanwhile, at Rs 456.20 per share at 0930 hours IST on BSE, the stock was trading down by 11.1%. It witnessed a spurt in the volume by more than 41.48 times. The stock hit a high of Rs 468 and a low of Rs 437 in the morning session.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.